Open-label, multicenter, phase 1/2 dose-escalation study of AME-133v (LY 2469298), administered intravenously in four weekly doses, in subjects with CD20+ follicular relapsed or refractory non-Hodgkin's lymphoma.

Trial Profile

Open-label, multicenter, phase 1/2 dose-escalation study of AME-133v (LY 2469298), administered intravenously in four weekly doses, in subjects with CD20+ follicular relapsed or refractory non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Ocaratuzumab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Applied Molecular Evolution
  • Most Recent Events

    • 11 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2010 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top